Cor Innova
Medical Devices, 2450 Holcombe BLVD, Houston, Texas, 77021, United States, 1-10 Employees
Phone Number: 13*********
Who is CORINNOVA
Johnson & Johnson Innovation JLABS @ TMC, Houston. With a lead investment from the UK-based Wellcome Trust, a premier international medical foundation, CorInnova is developing a non-blood...
Read More
-
Headquarters: 2450 Holcombe BLVD, Houston, Texas, 77021, United States
-
Date Founded: 2004
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
William Altman
Email
Phone
Industry: Medical Devices
SIC Code: 3845
|
NAICS Code: 334510 |
Show More
CorInnova Org Chart and Mapping
Similar Companies to CorInnova
Alleviant Medical
-
11-50
-
$ 1 Million to 5 Million
CereVasc
-
1-10
-
$ 1 Million to 5 Million
Tympanogen
-
1-10
-
$ Under 1 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding CorInnova
Answer: CorInnova's headquarters are located at 2450 Holcombe BLVD, Houston, Texas, 77021, United States
Answer: CorInnova's phone number is 13*********
Answer: CorInnova's official website is https://corinnova.com
Answer: CorInnova's revenue is $5 Million to $10 Million
Answer: CorInnova's SIC: 3845
Answer: CorInnova's NAICS: 334510
Answer: CorInnova has 1-10 employees
Answer: CorInnova is in Medical Devices
Answer: CorInnova top competitors include: Alleviant Medical , CereVasc , Tympanogen
Answer: CorInnova contact info: Phone number: 13********* Website: https://corinnova.com
Answer: Johnson & Johnson Innovation JLABS @ TMC, Houston. With a lead investment from the UK-based Wellcome Trust, a premier international medical foundation, CorInnova is developing a non-blood contacting cardiac assist device. CorInnova's device is a transformative biventricular device to treat acute heart failure. The technology will create a new paradigm for treatment. The device is designed to eliminate 40% of the adverse events associated with existing cardiac assist technologies, and may expand eligible patients by 3 to 4 times. The device may reverse the progression of HF, a blockbuster application. The device deploys minimally invasively into the pericardial sac in under 30 seconds, and has shown the ability to increase cardiac output by up to 50%. Addressable markets are up to $8 billion.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month